newsfilter
← Latest News
Business Wire·

Repare Therapeutics Provides Business and Clinical Update and Reports Second Quarter 2024 Financial Results

Reiterated guidance on data readout from MYTHIC trial evaluating lunresertib and camonsertib in patients with platinum-resistant ovarian and endometrial cancers in Q4 2024 Granted Fast Track designation by the FDA for